Previous close | 1.0300 |
Open | 1.0100 |
Bid | 0.9300 |
Ask | 1.0200 |
Strike | 62.50 |
Expiry date | 2025-01-17 |
Day's range | 1.0100 - 1.0400 |
Contract range | N/A |
Volume | |
Open interest | 2.07k |
Merck (MRK), Sanofi (SNY), Novartis (NVS) and AstraZeneca (AZN) announce their first-quarter results.
Fusion (FUSN) is expected to provide updates regarding the developmental program of its lead candidate, FPI-2265, for prostate cancer in the first-quarter earnings release.
AstraZeneca CEO Pascal Soriot joined Yahoo Finance to discuss the company's earnings today.